Abstract: Objective To investigate the association between holliday junction recognition protein（HJURP） gene polymorphism and oxaliplatin-based chemotherapy efficacy and adverse reactions in the first-line treatment for patients with advanced hepatocellular carcinoma（HCC）. Methods The clinical data and peripheral blood samples of 42 patients with advanced HCC received first-line treatment with oxaliplatin-based chemotherapy in Guangxi Medical University Cancer Hospital were collected. The next-generation sequencing（NGS） technology was used to classify the 7 loci of HJURP gene，and the relationship between gene polymorphism and chemotherapy efficacy，prognosis and adverse reactions was analyzed. Results Disease control rate（DCR）of 42 patients was 21.4%，and the polymorphism of HJURP gene was not related to DCR（P＞0.05）. The median progression-free survival（mPFS） was 1.5 months and the median overall survival（mOS） was 4.4 months. The mOS of patients carrying rs3771333 loci with A/A genotype was longer than those with A/C genotype（6.0 months vs 1.3 months，P=0.016）. The polymorphism of HJURP gene was not associated with hematotoxicity，gastrointestinal toxicity and neurotoxicity of oxaliplatin-based chemotherapy. Conclusions The rs3771333 polymor-phism of HJURP gene is associated with the prognosis of oxaliplatin-containing regimens in the treatment of advanced HCC，and patients with A/A genotype have better prognosis.

Key words: Hepatocellular carcinoma, HJURP, Single nucleotide polymorphism, Efficacy, Adverse reaction